TRAF-interacting protein (TRIP) is a RING-dependent ubiquitin ligase

Area of Science:

• * Molecular biology
• * Biochemistry
• * Immunology

Background:

• * TRAF-interacting protein (TRIP) was identified as a binding partner for TRAF1 and TRAF2, with a previously unknown mechanism for inhibiting NF-kappaB activation.
• * Sequence analysis revealed TRIP possesses an N-terminal RING domain, characteristic of E3 ubiquitin ligases.

Purpose of the Study:

• * To investigate the enzymatic activity and biological function of TRIP.
• * To determine if the RING domain is essential for TRIP's ligase activity and protein interactions.
• * To assess TRIP's role in NF-kappaB signaling, TNF-induced apoptosis, and osteoclastogenesis.

Main Methods:

• * Protein expression and purification.
• * In vitro ubiquitination assays to assess E3 ligase activity.
• * Co-immunoprecipitation assays to analyze protein-protein interactions.
• * Stable cell line expression of TRIP and its mutants.
• * Analysis of NF-kappaB pathway activation (IKK activation), TNF-induced apoptosis, and RANKL-induced osteoclastogenesis.

Main Results:

• * TRIP functions as a RING-dependent E3 ubiquitin ligase, demonstrating auto-ubiquitination.
• * An intact RING domain is required for TRIP's ligase activity.
• * TRIP interacts with TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6, but not CYLD or NIK.
• * Stable expression of TRIP or its RING mutant did not impact IKK activation, TNF-induced apoptosis, or RANKL-induced osteoclastogenesis.
• * TRIP expression decreased during later stages of osteoclastogenesis.

Conclusions:

• * TRIP is a novel RING-dependent E3 ubiquitin ligase.
• * TRIP acts as a binding partner for multiple TRAF proteins.
• * The identified E3 ligase activity of TRIP does not appear to mediate canonical NF-kappaB signaling or osteoclastogenesis under the tested conditions.